Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q86454198)
Watch
English
Angiogenesis in gastric cancer: hitting the target?
scientific article published on 03 October 2013
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
24094766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 February 2020
title
Angiogenesis in gastric cancer: hitting the target?
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
24094766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 February 2020
author name string
David H Ilson
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
24094766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 February 2020
language of work or name
English
0 references
publication date
3 October 2013
1 reference
stated in
Europe PubMed Central
PubMed publication ID
24094766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 February 2020
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed publication ID
24094766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 February 2020
volume
383
1 reference
stated in
Europe PubMed Central
PubMed publication ID
24094766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 February 2020
issue
9911
1 reference
stated in
Europe PubMed Central
PubMed publication ID
24094766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 February 2020
page(s)
4-6
1 reference
stated in
Europe PubMed Central
PubMed publication ID
24094766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 February 2020
cites work
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predictive biomarkers for bevacizumab: are we there yet?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961892-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(13)61892-9
1 reference
stated in
Europe PubMed Central
PubMed publication ID
24094766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 February 2020
PubMed publication ID
24094766
1 reference
stated in
Europe PubMed Central
PubMed publication ID
24094766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 February 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
